Papaverine
| Papaverine | |
|---|---|
| Salts [] | |
|---|---|
| Papaverine hydrochloride | |
| Papaverine sulfate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 339.40 g/mol [1] |
| Appearance | White prisms from alcohol-diethyl ether; needles from petroleum ether [1] |
| Density | 1.337 g/cu cm at 20 °C [1] |
| Melting point | 226 (dec) °C [1] |
| Boiling point | Sublimes at 135 °C [1] |
| Decomposition | When heated to decomposition it emits toxic fumes of /oxides of nitrogen/. [1] |
| Solubility | In water, 3.733X10-5 mg/L at 37.5 °C [1] |
| Predicted LogP | 3.9 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C20H21NO4 |
| IUPAC name | 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline |
| SMILES | COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC |
| InChI | InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3 |
| InChIKey | XQYZDYMELSJDRZ-UHFFFAOYSA-N |
| CAS number | 58-74-2 |
| UNII | DAA13NKG2Q |
| PubChem CID | 4680 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 1.5–2 hours |
| Metabolism | Hepatic |
| Excretion | Renal |
| Routes of administration | By mouth, intravenous, intramuscular, rectal, intracavernosal |
| Toxicity [] | |
|---|---|
| LD50 | Mouse: - intradermal: 150 mg/kg - intramuscular: 175 mg/kg - intravenous: 25 mg/kg - intravenous: 27.5 mg/kg [1] |
Papaverine (also known as Robaxapap, 6,7-Dimethoxy-1-veratrylisoquinoline, 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline, Pavatym, Pavacap, Papaverinum, 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline, Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, Isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy- or 200-397-2) is a substance of the phenol class.
It is a constituent of opium.
Chemistry
Salts []
Stereochemistry []
Papaverine is achiral.
Druglikeness
Lipinski's rule of five
Papaverine matches Lipinski's rule of five.Reagents
There are currently 4 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | no color change | |
| Mecke | dark blue | |
| Froehde | light green | |
| Ehrlich | no color change |
Pharmacology
ATC Classification
- alimentary tract and metabolism (A)
- drugs for functional gastrointestinal disorders (A03)
- drugs for functional gastrointestinal disorders (A03A)
- papaverine and derivatives (A03AD)
- papaverine (A03AD01)
- genito urinary system and sex hormones (G)
- urologicals (G04)
- urologicals (G04B)
- drugs used in erectile dysfunction (G04BE)
- papaverine (G04BE02)
MeSH Classification
Mechanism of action []
Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy. [1]
Medical side effects []
18 side effects listed on drug labels in SIDER 4.1 (papaverine).
- Decreased appetite
- Constipation
- Diarrhoea
- Dermatitis
- Rash
- Flushing
- Headache
- Hepatitis
- Nausea
- Vertigo
- Malaise
- Discomfort
- General discomfort
- Feeling abnormal
- Ill-defined disorder
- Abdominal discomfort
- Sedation
- Blood pressure increased
Indications
- Abdominal colic
- Acute myocardial infarction
- Angina pectoris
- Coronary artery occlusion
- Muscle spasms
- Peripheral vascular disorder
- Pulmonary embolism
- Vasospasm
Legal status []
- Australia: Papaverine is a Schedule 4.
- United States: Papaverine is Prescription only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4680, Papaverine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4680
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Papaverine. UNII: DAA13NKG2Q. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/DAA13NKG2Q
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 16:01:48 |
| drugspro | ok | 2026-11-20 16:01:44 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 16:01:44 |
| gsrs | ok | 2026-11-20 16:01:46 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015245) | 2026-11-20 16:01:44 |
| kegg | ok | 2026-11-20 16:01:46 |
| pubchem | ok | 2026-11-20 16:01:43 |
| missing (no r/tripreports posts mention it) | 2026-11-20 16:01:44 | |
| sider | ok | 2026-11-20 16:01:44 |
| structure | ok | 2026-11-20 16:01:44 |
| wikipedia | ok | 2026-11-20 16:01:44 |